Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients
https://doi.org/10.22416/1382-4376-2017-27-5-65-68
Abstract
Aim. To estimate efficacy and safety of direct antiviral drugs for hepatitis C treatment in donor lung recipients. Key points. The first cases in Russian literature and one of the first-ever cases of hepatitis C treatment by direct antiviral agents in lung transplant recipients are presented. Combined therapy by asunaprevir and daclatasvir for 24 weeks resulted in sustained virologic response. No significant adverse effects on drug to drug interactions, except for mild and controllable alteration of tacrolimus blood level, were noted. Conclusion. Daclatasvir and asunaprevir combination is effective and safe treatment mode for hepatitis C in donor lung recipients
About the Authors
D. T. Abdurakhmanov
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Ye. . Sidorova
Federal state educational government-financed institution of higher education «Lomonosov Moscow State University»
Russian Federation
Russian Federation
I. N. Tikhonov
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
N. A. Mukhin
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. T. Ivashkin
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Всемирная организация здравоохранения. Глобальное предупреждение и ответные действия (GAR). Hepatitis C. 2012 (http://www.who.int/csr/disease/ hepatitis/ whocdscsrlyo2003/en/index4.html).
2. Breitenfeldt M., Rasenack J., Berthold H. et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16:130-6.
3. Neumann U., Berg T., Bahra M. et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77:226-31.
4. Doucette K.E., Halloran K., Kapasi A., Lien D., Weinkauf J.G. Outcomes of lung transplantation in recipients with hepatitis C virus infection. Am J Transplant 2016; 16:2445-52.
5. Sahi H., Zein N., Mehta A., Blazey H., Meyer K., Budev M. Outcomes after lung transplantation in patients with chronic hepatitis C virus infection. J Heart Lung Transplant 2007; 26:466-71.
6. Garcha P., Fadul R., Kapoor A. et al. Long-Term Outcomes of Lung Transplantation (LT) in Hepatitis C Positive (HCVþ) Patients. J Heart Lung Transplant 2013; 32:4S, A108.
7. Koenig A., Stepanova M., Saab S., Ahmed A., Wong R., Younossi Z.M. Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry. Aliment Pharmacol Ther 2016; 44:271-8.
8. Carreno M., Piedad U., Maite L. et al. Hepatitis C virus infection after lung transplantation: Dim prognosis. J Heart Lung Transplant 2001; 20:224.
9. Manns M., Pol S., Jacobson I. et al; HALLMARK- DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384:1597-605.
10. Ueda Y., Kaido T., Hatano E., Ohtsuru S., Uemoto S. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. Hepatol Res 2015; 45:1360-2.
11. Ozaras R., Mete B., Yemisen M., Balkan I., Alkan M., Tabak F. Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir (letter to editor). J Gastrointest Liver Dis 2015; 24:393-4.
12. Kumada H., Suzuki Y., Ikeda K. et al. Daclatasvir plus asunaprevir for chronic hcv genotype 1b infection. Hepatology 2014; 59:2083-91.
13. Doucette K., Sumner S., Weinkauf J. Treatment of hepa- titis C in a lung transplant recipient with sofosbuvir and daclatasvir. J Heart Lung Transplant 2016; 35(6):840-1.
14. D’Ambrosio R., Aghemo A., Rossetti V., Carrinola R., Colombo M. Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. Liver International 2016; 1-5. DOI: 10.1111/liv.13203
15. Weill D., Benden C., Corris P.A. et al. A consensus document for the selection of lung transplant candidates: 2014 - An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1-15.
16. Ueda Y., Uemoto S. Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation. Transplant International 2016; 29:119-21.
Review
For citations:
Abdurakhmanov D.T., Sidorova Ye., Tikhonov I.N., Mukhin N.A., Ivashkin V.T. Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):65-68. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-5-65-68
Views:
732
Email this article 
